There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Subscribe To Our Newsletter & Stay Updated
